ITCI - イントラセルラ―・セラピ―ズ (Intra-Cellular Therapies Inc.) イントラセルラ―・セラピ―ズ

 ITCIのチャート


 ITCIの企業情報

symbol ITCI
会社名 Intra-Cellular Therapies Inc (イントラセルラ―・セラピ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 イントラ・セルラー・セラピーズ(Intra-Cellular Therapies Inc.)はバイオ医薬品会社である。同社は中枢神経系(CNS)内の細胞内シグナル伝達機構を標的とすることにより、神経精神医学的および神経学的障害における不十分な医学的ニーズに対処する小分子薬物の発見・臨床開発を行う。同社は神経学的および精神医学的障害の治療のための薬物を発見・開発する。ルマテペロン(ITI-007)は、主要製品候補である。同社の双極性うつ病プログラムは、2つの第III相多施設、無作為化、二重盲検、プラセボ対照臨床試験で構成される。1つは単独治療としてルテテペロンを評価し、もう1つはリチウムまたはバルプロエートによる補助療法としてルテテペロンを評価する。同社は、アルツハイマー病(AD)を含む認知症患者の激越の治療のためのルテテペロンの第III相開発を開始した。   イントラセルラ―・セラピ―ズは、米国のバイオ製薬企業。中枢神経系内の細胞内シグナル伝達機構を標的とする神経精神障害および神経障害に対処する小分子薬の発見と臨床開発に焦点を当てる。主要製品候補は、統合失調症のためのファ―ストインクラスの治療薬「ITI-007」、統合失調症および認知障害の治療薬「 ITI-002」がある。   Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.
本社所在地 430 East 29th Street New York NY 10016 USA
代表者氏名 Lawrence J. Hineline ローレンスJ.ヒネリン
代表者役職名 Chief Financial Officer Vice President - Finance Treasurer Assistant Secretary
電話番号 +1 212-923-3344
設立年月日 41122
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 49人
url www.intracellulartherapies.com
nasdaq_url https://www.nasdaq.com/symbol/itci
adr_tso
EBITDA EBITDA(百万ドル) -132.42960
終値(lastsale) 18.42
時価総額(marketcap) 1007744790.24
時価総額 時価総額(百万ドル) 996.25590
売上高 売上高(百万ドル) 0.03581
企業価値(EV) 企業価値(EV)(百万ドル) 592.49140
当期純利益 当期純利益(百万ドル) -127.03560
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Intra-Cellular Therapies Inc revenues decreased from $210K to $0K. Net loss increased 63% to $72.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 91% to $59.3M (expense) General and administrative - Balancing v increase of 20% to $8.3M (expense).

 ITCIのテクニカル分析


 ITCIのニュース

   Intra-Cellular Therapies (NASDAQ:ITCI) Upgraded to Buy by Zacks Investment Research  2020/10/23 06:40:46 Dakota Financial News
Intra-Cellular Therapies (NASDAQ:ITCI) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday, Zacks.com reports. The firm currently has a $29.00 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target would suggest a potential upside of 12.62% from the stock’s previous […]
   Intra-Cellular Therapies (NASDAQ:ITCI) Downgraded by Zacks Investment Research to Hold  2020/10/21 08:14:47 Dakota Financial News
Zacks Investment Research lowered shares of Intra-Cellular Therapies (NASDAQ:ITCI) from a buy rating to a hold rating in a report issued on Tuesday morning, Zacks.com reports. According to Zacks, “Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous […]
   Intra-Cellular Therapies (NASDAQ:ITCI) Rating Lowered to Hold at Zacks Investment Research  2020/10/21 08:14:47 Zolmax News
Zacks Investment Research cut shares of Intra-Cellular Therapies (NASDAQ:ITCI) from a buy rating to a hold rating in a report released on Tuesday morning, Zacks.com reports. According to Zacks, “Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous […]
   2020-2025: Stress Management Drug Market Evolving Opportunities & Advancement with Top Key Players: Actavis Generics, Sanofi, Janssen, Pfizer, Intra-Cellular Therapies, Alkermes, Otsuka  2020/10/07 11:28:53 OpenPR
Global Stress Management Drug Market 2020-2025 examines the market in detail along with focusing on significant market dynamics for the key players in the market. This research report offers granulated yet in-depth analysis of revenue share, market segments, revenue
   Intra-Cellular Therapies Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer  2020/10/01 20:30:00 GlobeNewswire
NEW YORK, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and…
   Intra-Cellular, Qorvo rise; Slack, Tiffany fall  2020/09/09 20:38:48 ABC News
Stocks that moved heavily or traded substantially Wednesday: Intra-Cellular, Qorvo rise; Slack, Tiffany fall
   Implied Volatility Surging for Intra-Cellular Therapies (ITCI) Stock Options  2020/06/04 12:49:00 Zacks Investment Research
Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.
   Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Misses Revenue Estimates  2020/05/07 15:05:04 Zacks Investment Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 25.51% and -38.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   What Awaits Intra-Cellular Therapies (ITCI) in Q4 Earnings?  2020/02/18 15:13:00 Zacks Investment Research
Intra-Cellular Therapies (ITCI) is likely to provide update on its commercialization plan for Caplyta, approved for treating schizophrenia in December 2019, on the Q4 call.
   Intra-Cellular Sinks on Large Share Offering  2020/01/07 15:00:15 Baystreet.ca
Intra-Cellular Therapies Inc (NASDAQ:ITCI) reported a proposed public offering of 10,000,000 shares of common stock. The New York-based Intra-Cellular is a biopharmaceutical company founded on Nobel prize-winning research that allows it to understand …
   Intra-Cellular, Qorvo rise; Slack, Tiffany fall  2020/09/09 20:38:48 ABC News
Stocks that moved heavily or traded substantially Wednesday: Intra-Cellular, Qorvo rise; Slack, Tiffany fall
   Implied Volatility Surging for Intra-Cellular Therapies (ITCI) Stock Options  2020/06/04 12:49:00 Zacks Investment Research
Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.
   Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Misses Revenue Estimates  2020/05/07 15:05:04 Zacks Investment Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 25.51% and -38.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   What Awaits Intra-Cellular Therapies (ITCI) in Q4 Earnings?  2020/02/18 15:13:00 Zacks Investment Research
Intra-Cellular Therapies (ITCI) is likely to provide update on its commercialization plan for Caplyta, approved for treating schizophrenia in December 2019, on the Q4 call.
   Intra-Cellular Sinks on Large Share Offering  2020/01/07 15:00:15 Baystreet.ca
Intra-Cellular Therapies Inc (NASDAQ:ITCI) reported a proposed public offering of 10,000,000 shares of common stock. The New York-based Intra-Cellular is a biopharmaceutical company founded on Nobel prize-winning research that allows it to understand …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 イントラセルラ―・セラピ―ズ ITCI Intra-Cellular Therapies Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)